This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Pneumococcal Vaccines Market

Market Insights on Pneumococcal Vaccines covering sales outlook, demand forecast & up-to-date key trends

Pneumococcal Vaccines Market by Product Type (Pneumococcal Polysaccharide Vaccines, Pneumococcal Conjugate Vaccines), Distribution Channel (Pharmacies, Community Clinics, Public Health Agencies) & Region - Forecast to 2021-2031

Pneumococcal Vaccines Market Snapshot

[187 pages] According to a survey conducted by ESOMAR-certified consulting firm Future Market Insights (FMI), the Pneumococcal Vaccines Market value is expected to total US$ 10.1 Bn in 2021. Driven by the rising prevalence of pneumococcal diseases across the globe, sales of pneumococcal vaccines are poised to increase by a CAGR of 7.3% over the forecast period 2021-2031.

Favored by the increasing number of government initiatives and growing awareness regarding the benefits of early vaccination, the pneumococcal vaccines market is likely to register an impressive year-on-year growth at 9.60% in 2021.

Customize this Report

Let us know your requirement to get
100% FREE customization

Key Points Covered in Pneumococcal Vaccines Market Study

  • Market estimates and forecast 2021-2031
  • Key drivers and restraints impacting market growth
  • Segment-wise, Country-wise, and Region-wise Analysis
  • Competition Mapping and Benchmarking
  • Brand share and Market Share Analysis
  • Key Product Innovations and Regulatory Climate
  • COVID-19 Impact on Pneumococcal Vaccines Market and How to Navigate
  • Recommendation on Key Winning Strategies

Pneumococcal Vaccines Market Historic Outlook Compared to the Forecast Period 2021-2031

The pneumococcal vaccines market grew at 8.90% CAGR between 2016 and 2020. The growth of the market can be attributed to the increasing prevalence of pneumococcal diseases such as bacteremic pneumonia, bloodstream infection, meningitis, bacteremia, and middle ear infection.

Pneumococcal Vaccines Market Download Report Brochure

According to a study by the National Foundation for Infectious Diseases (NFID), nearly 1.3 million people in the U.S. visit emergency departments due to pneumonia, which causes death of around 50,000 people. The fatality rate is even higher in patient aged above 65 years.

The rising number of smokers, diabetes patients, heavy drinkers, and individuals living with chronic health conditions, who are vulnerable to infections and ailments due to their weakened immune system will create demand for pneumococcal vaccines.

Some of the leading manufacturers are taking initiatives to curb the incidence of pneumococcal diseases in Gavi-supported countries. For instance, in January 2018, Pfizer, one of the global pharmaceutical leaders, announced reducing the price of its PCV-13 4 dose vial vaccine from US$ 3.05 to US$ 2.95 per dose in Gavi-supported countries.

These developments are expected to create growth opportunities, enabling the market to expand at a CAGR of 9.60% through 2031.

What is the Impact of the Novel Coronavirus Outbreak on the Sales of Pneumococcal Vaccines?

The unprecedented outbreak of COVID-19 has substantially impacted the economies across the world. Various businesses and markets have been affected due to the regulatory lockdowns and imposed by the government, impeding the overall growth of industries.

However, the pandemic has positively impact the pneumococcal vaccines market, bolstering the sales over the past two years.

Some of the cases of novel coronavirus were placed in the same genre of diseases like pneumonia. Due to high similarities between coronavirus and pneumonia, medical professionals are increasingly using pneumococcal vaccines as a preventative measure against the high risk of lung infections caused by the disease.

According to a report published by World Health Organization (WHO) on 4th August 2021, approximately 199,466,211 cases has been confirmed across the globe with over 4,244,541 fatalities.

This rising cases of COVID-19 coupled with emerging new strains of coronavirus such asOC43, HKU1, and SARS-CoV among other is creating remunerative opportunities for the market.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

How are Government Initiatives Driving Pneumococcal Vaccines Market?

Governments across various countries are adopting various initiatives to reduce the burden of pneumococcal diseases. For instance, in India, the Ministry of Health and Family Welfare (MoHFW) has undertaken initiative named, Social Action and Awareness to Neutralise Pneumonia Successfully (SAANS). The goal of SAANA is to spread the awareness regarding the routine pneumococcal immunization programs to curb the incidence of pneumonia.

Similarly, international organizations are contributing towards the goal. For instance, the WHO and United Nations Children’s Emergency Fund (UNICEF) have also introduced an initiative named, the Integrated Global Action Plan for the Prevention and Control of Pneumonia and Diarrhoea (GAPPD). The aim of GAPPD is to protect, prevent, and treat children from pneumonia and diarrhea.

Due to the efforts of these organization, several countries across the globe are progressively introducing pneumococcal conjugate vaccine (PCV) for infants and children aged from 6 weeks to 5 years for routine immunization and to prevent pneumococcal diseases and acute otitis media. As per a report by the World Health Organization (WHO), pneumococcal vaccine have been introduce in over 134 countries by the end of 2016 and covering about 42% of the world.

Thus, government initiatives are expected to help the pneumococcal vaccines market to expand over the coming year.

Pneumococcal Vaccines Market - Country-wise Insights

Why is Demand for Pneumococcal Vaccines Rising in the U.S.?

As per the FMI, the U.S. is anticipated to dominate the market in North America. The market for pneumococcal vaccines in the U.S. is bolstering due to high prevalence of pneumococcal disorders such as bacteremic pneumonia, bloodstream infection, and meningitis.

As per a report by the Centers of Disease Control and Prevention, more than 150,000 people in in the U.S. are hospitalized because of the pneumococcal pneumonia and around 3,500 people die due to pneumococcal meningitis and bacteremia. Thus, with the rise in prevalence of these diseases, the market in the U.S. is expected to expand at a rapid pace.

How is the Market for Pneumococcal Vaccines Flourishing in the U.K.?

In Europe, the U.K. is emerging as the most lucrative market on the back on presence of some of the leading pharmaceutical companies such as GlaxoSmithKline (GSK), AstraZeneca, Pfizer UK, and Shire.

Growing number of clinical trials and research and development activities for development of effective pneumococcal vaccines is estimated to provide enormous opportunities for the growth of the market. This will also fulfil the demand for vaccines for multiple serotypes in the country.

Owing to the presence of well-developed medical infrastructure and high consumer spending on the healthcare, the market in the U.K. is likely to project a steady growth over the coming years.

Why is the Demand for Pneumococcal Vaccines Spurring in India?

Issues concerning rising prevalence of pneumococcal diseases among children under the age of five have is increasing with urbanization in the country. As per a report published by Johns Hopkins Bloomberg School of Public Health named, Pneumonia & Diarrhea report 2020, India account for the largest number of deaths of children bellow 5 year out of 15 countries.

Thus to curb the burden of these diseases, government of the country is increasing undertaking initiatives to spread the awareness regarding the pneumococcal diseases.

For instance, Global Coalition against Child Pneumonia (GCCP) committee form by the government to promote interventions for protecting, preventing, and treating pneumonia is celebrating World Pneumonia Day in 12th November. This is to spread awareness regarding pneumonia and highlight the seriousness of disease as a public health problem across the country. Such initiatives are expected to propelling the demand for pneumococcal vaccines in India.

What are the Growth Prospects for Pneumococcal Vaccines Market in China?

A steady rise in investment across the medical healthcare has be witnessed in China, especially, due to the outbreak of coronavirus in the country. According to a report by WHO, around 121,067 cases of coronavirus has been reported in China with a 5,639 death over the last year.

Owing to the increasing use of pneumococcal vaccines by the medical institutes in the treatment of COVID-19, China is estimated to emerge as one of the most remunerative market in landscape.

Increasing number of medical institutes and hospitals in the country is also expected to bolster the sales of pneumococcal vaccines in the country.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Pneumococcal Vaccines Market- Category-wise Insights

Why is Demand for Pneumococcal Conjugate Vaccines High?

Pneumococcal conjugate vaccines are estimated to lead the product type, registering high growth in the global pneumococcal vaccines market.

Increasing adoption of pneumococcal conjugate vaccines for routine immunization of kids below 5 years to prevent them from fatal pneumococcal diseases and acute otitis media across the developing economies is projected to spur the sales.

In response to increasing number of research and development activities for developing new conjugate vaccines for expanding indications, the segment is likely to witness vigorous growth at through 2031.

Why do the Public Health Agencies Account for Maximum Share in Pneumococcal Vaccines Sales?

Among pharmacies, public health agencies, and community clinics, public health agencies are anticipated to account for the largest market share driven by the large amount of vaccine purchases by the organization such as WHO, GAVI, UNICEF, and other.

These organization purchase massive amount of pneumonia vaccines from the manufacturers to distribute them directly to the destination geographies for the social cause. Thus, on account of increasing number of initiatives undertaken by these organization, the segment is expected to emerge as the center point for the expansion of the market.

Pneumococcal Vaccines Market - Competitive Landscape

Leading players operating in the pneumococcal vaccines market are focusing on research and development for new product development to enhance their product portfolio and engaging into strategic collaboration, agreement, merger & acquisition with other market players to gain competitive edge over other players. For instance,

  • Merck & Co., Inc., is focusing on developing new Merck’s V114, 15-valent pneumococcal conjugate vaccine. In September 2020, the company announced results for V114 from phase 2 & phase 3 studies and its respond on all 15 serotypes of pneumonia.
  • In September 2020, Shinogi, a Japanese pharmaceutical company announced entering into a license agreement with a next-generation nasal vaccines manufacturer. HanaVax. The agreement with assist the company in R&D, manufacturing, commercialization, and distribution of Streptococcus pneumoniae developed by HanaVax.  

Pneumococcal Vaccines Market - Scope of Report

Attribute

Details

Forecast Period

2021-2031

Historical Data Available for

2016-2020

Pneumococcal Vaccines Market Analysis

USD Million for Value

Key Regions Covered

North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East & Africa

 

Key Countries Covered

US, Canada, Germany, U.K., France, Italy, Spain, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Turkey, Northern Africa, and South Africa

Pneumococcal Vaccines Market - Key Segments Covered

Product Type, Distribution Channel, and Regions

Pneumococcal Vaccines Market - Key Companies Profiled

  • Glaxosmithkline plc.
  • LG Chem Ltd.
  • Merck & Co., Inc.
  • Panacea Biotec Limited
  • Pfizer Inc.
  • Pnuvax Incorporated
  • Serum Institute of India Pvt. Ltd.
  • Shenzhen Kangtai Biological Products Co., Ltd.
  • SK Bioscience
  • Walvax Biotechnology Co., Ltd.

Pneumococcal Vaccines Market - Report Coverage

Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Pneumococcal Vaccines Market by Category

By Product Type:

  • Pneumococcal Polysaccharide Vaccines
  • Pneumococcal Conjugate Vaccines

By Distribution Channel:

  • Pharmacies
  • Community Clinics
  • Public Health Agencies
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific Excluding Japan
  • Japan
  • Oceania
  • MEA

Frequently Asked Questions

The pneumococcal vaccines market is expected to surpass a valuation of US$ 10124.9 in 2021.

The pneumococcal vaccines market witnessed impressive growth at 8.90% CAGR between 2016 and 2020.

Expansion of product indication and increasing Pharmacy-based Immunization Services (PBIS) will spur the sales.

GlaxoSmithKline Plc., Pfizer Inc., Merck & Co., Inc., and Sanofi SA. are the top players leading the pneumococcal vaccines market.

Demand for infant formula will continue to rise backed by rising prevalence of pneumococcal diseases in the country, sales across North America are set to surge at a robust CAGR of 8.25% through 2031.

The market for pneumococcal vaccines in Europe will exhibit a steady growth at 7.39% CAGR during the forecast period 2021-2031.

Top countries in terms of pneumococcal vaccines sales are the U.S., France, Germany, Canada, and the U.K.

Leading players of global pneumococcal vaccines market is expected to contribute around 85-90% of total market share.

In 2021 key countries that are Japan and South Korea are estimated to account for 5% and less than 1% market share respectively in global pneumococcal vaccines market.

Table of Content

1. Executive Summary

    1.1. Market Overview

    1.2. Market Analysis

    1.3. FMI Analysis and Recommendations

    1.4. Wheel of Fortune

2. Market Introduction

    2.1. Market Taxonomy

    2.2. Market Definition

3. Pneumococcal Vaccines Market Opportunity Analysis

    3.1. Macro-Economic Factors

    3.2. Opportunity Analysis

4. Market Background

    4.1. Market Dynamics

        4.1.1. Drivers

        4.1.2. Restraints

        4.1.3. Key Trends

5. Key Inclusions

    5.1. Disease Epidemiology

    5.2. Reimbursement Scenario

    5.3. Pipeline Assessment

6. Respiratory Syncytial Virus (RSV) Vaccines Market, Pipeline Assessment

7. North America Pneumococcal Vaccines Market Analysis 2016–2020 and Forecast 2021–2031

    7.1. Introduction

    7.2. Historical Market Size (US$ Mn) Analysis By Country, 2016–2020

        7.2.1. U.S.

        7.2.2. Canada

    7.3. Market Size (US$ Mn) Forecast By Country, 2021–2031

    7.4. Historical Market Size (US$ Mn) Trend Analysis By Product Type, 2016–2020

        7.4.1. Pneumococcal Conjugate Vaccines

        7.4.2. Pneumococcal Polysaccharide Vaccines

    7.5. Market Size (US$ Mn) Forecast By Product Type, 2021–2031

    7.6. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2016–2020

        7.6.1. Pharmacies

        7.6.2. Community Clinics

        7.6.3. Public Health Agencies

        7.6.4. Others

    7.7. Market Size (US$ Mn) Forecast By Distribution Channel, 2021–2031

    7.8. Market Attractiveness Analysis

        7.8.1. By Country

        7.8.2. By Product

        7.8.3. By Distribution Channel

    7.9. Key Market Participants – Intensity Mapping

8. Latin America Pneumococcal Vaccines Market Analysis 2016–2020 and Forecast 2021–2031

    8.1. Introduction

    8.2. Historical Market Size (US$ Mn) By Country, 2016–2020

        8.2.1. Brazil

        8.2.2. Mexico

        8.2.3. Rest of Latin America

    8.3. Market Size (US$ Mn) Forecast By Country, 2021–2031

    8.4. Historical Market Size (US$ Mn) Trend Analysis By Product Type, 2016–2020

        8.4.1. Pneumococcal Conjugate Vaccines

        8.4.2. Pneumococcal Polysaccharide Vaccines

    8.5. Market Size (US$ Mn) Forecast By Product Type, 2021–2031

    8.6. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2016–2020

        8.6.1. Pharmacies

        8.6.2. Community Clinics

        8.6.3. Public Health Agencies

        8.6.4. Others

    8.7. Market Size (US$ Mn) Forecast By Distribution Channel, 2021–2031

    8.8. Market Attractiveness Analysis

        8.8.1. By Country

        8.8.2. By Product

        8.8.3. By Distribution Channel

    8.9. Key Market Participants – Intensity Mapping

9. Western Europe Pneumococcal Vaccines Market Analysis 2016–2020 and Forecast 2021–2031

    9.1. Introduction

    9.2. Historical Market Size (US$ Mn) By Country, 2016–2020

        9.2.1. Germany

        9.2.2. France

        9.2.3. U.K.

        9.2.4. Spain

        9.2.5. Italy

        9.2.6. Rest of Western Europe

    9.3. Market Size (US$ Mn) Forecast By Country, 2021–2031

    9.4. Historical Market Size (US$ Mn) Trend Analysis By Product Type, 2016–2020

        9.4.1. Pneumococcal Conjugate Vaccines

        9.4.2. Pneumococcal Polysaccharide Vaccines

    9.5. Market Size (US$ Mn) Forecast By Product Type, 2021–2031

    9.6. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2016–2020

        9.6.1. Pharmacies

        9.6.2. Community Clinics

        9.6.3. Public Health Agencies

        9.6.4. Others

    9.7. Market Size (US$ Mn) Forecast By Distribution Channel, 2021–2031

    9.8. Market Attractiveness Analysis

        9.8.1. By Country

        9.8.2. By Product

        9.8.3. By Distribution Channel

    9.9. Key Market Participants – Intensity Mapping

10. Eastern Europe Pneumococcal Vaccines Market Analysis 2016–2020 and Forecast 2021–2031

    10.1. Introduction

    10.2. Historical Market Size (US$ Mn) By Country, 2016–2020

        10.2.1. Russia

        10.2.2. Poland

        10.2.3. Rest of Eastern Europe

    10.3. Market Size (US$ Mn) Forecast By Country, 2021–2031

    10.4. Historical Market Size (US$ Mn) Trend Analysis By Product Type, 2016–2020

        10.4.1. Pneumococcal Conjugate Vaccines

        10.4.2. Pneumococcal Polysaccharide Vaccines

    10.5. Market Size (US$ Mn) Forecast By Product Type, 2021–2031

    10.6. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2016–2020

        10.6.1. Pharmacies

        10.6.2. Community Clinics

        10.6.3. Public Health Agencies

        10.6.4. Others

    10.7. Market Size (US$ Mn) Forecast By Distribution Channel, 2021–2031

    10.8. Market Attractiveness Analysis

        10.8.1. By Country

        10.8.2. By Product

        10.8.3. By Distribution Channel

    10.9. Key Market Participants – Intensity Mapping

11. Asia Pacific excluding Japan and China (APEJ) Pneumococcal Vaccines Market Analysis 2016–2020 and Forecast 2021–2031

    11.1. Introduction

    11.2. Historical Market Size (US$ Mn) By Country, 2016–2020

        11.2.1. India

        11.2.2. China

        11.2.3. Australia and New Zealand

        11.2.4. ASEAN

        11.2.5. Rest of APEJ

    11.3. Market Size (US$ Mn) Forecast By Country, 2021–2031

    11.4. Historical Market Size (US$ Mn) Trend Analysis By Product Type, 2016–2020

        11.4.1. Pneumococcal Conjugate Vaccines

        11.4.2. Pneumococcal Polysaccharide Vaccines

    11.5. Market Size (US$ Mn) Forecast By Product Type, 2021–2031

    11.6. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2016–2020

        11.6.1. Pharmacies

        11.6.2. Community Clinics

        11.6.3. Public Health Agencies

        11.6.4. Others

    11.7. Market Size (US$ Mn) Forecast By Distribution Channel, 2021–2031

    11.8. Market Attractiveness Analysis

        11.8.1. By Country

        11.8.2. By Product

        11.8.3. By Distribution Channel

    11.9. Key Market Participants – Intensity Mapping

12. Japan Pneumococcal Vaccines Market Analysis 2016–2020 and Forecast 2021–2031

    12.1. Introduction

    12.2. Historical Market Size (US$ Mn) Trend Analysis By Product Type, 2016–2020

        12.2.1. Pneumococcal Conjugate Vaccines

        12.2.2. Pneumococcal Polysaccharide Vaccines

    12.3. Market Size (US$ Mn) Forecast By Product Type, 2021–2031

    12.4. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2016–2020

        12.4.1. Pharmacies

        12.4.2. Community Clinics

        12.4.3. Public Health Agencies

        12.4.4. Others

    12.5. Market Size (US$ Mn) Forecast By Distribution Channel, 2021–2031

    12.6. Market Attractiveness Analysis

        12.6.1. By Product

        12.6.2. By Distribution Channel

    12.7. Key Market Participants – Intensity Mapping

13. MEA Pneumococcal Vaccines Market Analysis 2016–2020 and Forecast 2021–2031

    13.1. Introduction

    13.2. Market Size (US$ Mn) Forecast By Country, 2021–2031

    13.3. Historical Market Size (US$ Mn) Trend Analysis By Product Type, 2016–2020

        13.3.1. Pneumococcal Conjugate Vaccines

        13.3.2. Pneumococcal Polysaccharide Vaccines

    13.4. Market Size (US$ Mn) Forecast By Product Type, 2021–2031

    13.5. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2016–2020

        13.5.1. Pharmacies

        13.5.2. Community Clinics

        13.5.3. Public Health Agencies

        13.5.4. Others

    13.6. Market Size (US$ Mn) Forecast By Distribution Channel, 2021–2031

    13.7. Market Attractiveness Analysis

        13.7.1. By Country

        13.7.2. By Product

        13.7.3. By Distribution Channel

    13.8. Key Market Participants – Intensity Mapping

14. Forecast Factors: Relevance and Impact

15. Drivers and Restraints: Impact Analysis

16. Macroeconomic Assumptions

17. Market Share Analysis

18. Competition Analysis

    18.1. Competition Dashboard

    18.2. Company Deep Dive

        18.2.1. Pfizer Inc.

            18.2.1.1. Overview

            18.2.1.2. Product Portfolio

            18.2.1.3. Production Footprint

            18.2.1.4. Sales Footprint

            18.2.1.5. Strategy

                18.2.1.5.1. Marketing Strategy

                18.2.1.5.2. Product Strategy

                18.2.1.5.3. Channel Strategy

        18.2.2. Merck & Co., Inc.

            18.2.2.1. Overview

            18.2.2.2. Product Portfolio

            18.2.2.3. Production Footprint

            18.2.2.4. Sales Footprint

            18.2.2.5. Strategy

                18.2.2.5.1. Marketing Strategy

                18.2.2.5.2. Product Strategy

                18.2.2.5.3. Channel Strategy

        18.2.3. GlaxoSmithKline plc.

            18.2.3.1. Overview

            18.2.3.2. Product Portfolio

            18.2.3.3. Production Footprint

            18.2.3.4. Sales Footprint

            18.2.3.5. Strategy

                18.2.3.5.1. Marketing Strategy

                18.2.3.5.2. Product Strategy

                18.2.3.5.3. Channel Strategy

        18.2.4. Sanofi SA

            18.2.4.1. Overview

            18.2.4.2. Product Portfolio

            18.2.4.3. Production Footprint

            18.2.4.4. Sales Footprint

            18.2.4.5. Strategy

                18.2.4.5.1. Marketing Strategy

                18.2.4.5.2. Product Strategy

                18.2.4.5.3. Channel Strategy

19. Global Pneumococcal Vaccines Market Analysis 2016–2020 and Forecast 2021–2031, By Region

    19.1. Introduction / Key Findings

    19.2. Historical Market Size (US$ Mn) Trend Analysis By Region, 2016–2020

        19.2.1. North America

        19.2.2. Western Europe

        19.2.3. Eastern Europe

        19.2.4. Latin America

        19.2.5. Asia Pacific excluding Japan

        19.2.6. Japan

        19.2.7. Middle East and Africa

    19.3. Market Size (US$ Mn) Forecast By Region, 2021–2031

    19.4. Market Attractiveness Analysis By Region

20. Global Pneumococcal Vaccines Market Analysis 2016–2020 and Forecast 2021–2031, By Product

    20.1. Introduction

    20.2. Historical Market Size (US$ Mn) Trend Analysis By Product Type, 2016–2020

        20.2.1. Pneumococcal Conjugate Vaccines

        20.2.2. Pneumococcal Polysaccharide Vaccines

    20.3. Market Size (US$ Mn) Forecast By Product Type, 2021–2031

    20.4. Market Attractiveness Analysis By Product Type

21. Global Pneumococcal Vaccines Market Analysis 2016–2020 and Forecast 2021–2031, By Distribution Channel

    21.1. Introduction

    21.2. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2016–2020

        21.2.1. Pharmacies

        21.2.2. Community Clinics

        21.2.3. Public Health Agencies

        21.2.4. Others

    21.3. Market Size (US$ Mn) Forecast By Distribution Channel, 2021–2031

    21.4. Market Attractiveness Analysis By Distribution Channel

22. Global Pneumococcal Vaccines Market Analysis 2016–2020 and Forecast 2021–2031

    22.1. Market Value Share Analysis

        22.1.1. By Country

        22.1.2. By Product

        22.1.3. By Distribution Channel

    22.2. Y-o-Y Growth Analysis

        22.2.1. By Country

        22.2.2. By Product

        22.2.3. By Distribution Channel

    22.3. Absolute $ Opportunity

23. Assumptions and Acronyms

24. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1a: Factors Considered While Setting Vaccine Prices, By Company

Table 1b: Factors Considered While Setting Vaccine Prices, By Company

Table 02a: Pneumococcal Vaccines Market Pipeline Analysis (2021)

Table 02b: Pneumococcal Vaccines Market Pipeline Analysis (2021)

Table 02c: Pneumococcal Vaccines Market Pipeline Analysis (2021)

Table 02d: Pneumococcal Vaccines Market Pipeline Analysis (2021)

Table 03a: RSV Vaccines Market Pipeline Analysis (2021)

Table 03b: RSV Vaccines Market Pipeline Analysis (2021)

Table 03c: RSV Vaccines Market Pipeline Analysis (2021)

Table 03d: RSV Vaccines Market Pipeline Analysis (2021)

Table 03e: RSV Vaccines Market Pipeline Analysis (2021)

Table 03f: RSV Vaccines Market Pipeline Analysis (2021)

Table 04: North America Pneumococcal Vaccines Market size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Country

Table 05: North America Pneumococcal Vaccines Market size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Product Type

Table 06: North America Pneumococcal Vaccines Market Size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Distribution Channel 

Table 07: Latin America Pneumococcal Vaccines Market size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Country

Table 08: Latin America Pneumococcal Vaccines Market size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Product Type

Table 09: Latin America Pneumococcal Vaccines Market Size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Distribution Channel 

Table 10: Western Europe Pneumococcal Vaccines Market size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Country

Table 11: Western Europe Pneumococcal Vaccines Market size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Product Type

Table 12: Western Europe Pneumococcal Vaccines Market Size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Distribution Channel 

Table 13: Eastern Europe Pneumococcal Vaccines Market size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Country

Table 14: Eastern Europe Pneumococcal Vaccines Market size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Product Type

Table 15: Eastern Europe Pneumococcal Vaccines Market Size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Distribution Channel 

Table 16: APEJ Pneumococcal Vaccines Market size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Country

Table 17: APEJ Pneumococcal Vaccines Market size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Product Type

Table 18: APEJ Pneumococcal Vaccines Market Size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Distribution Channel 

Table 19: Japan Pneumococcal Vaccines Market size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Product Type

Table 20: Japan Pneumococcal Vaccines Market Size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Distribution Channel 

Table 21: MEA Pneumococcal Vaccines Market size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Country

Table 22: MEA Pneumococcal Vaccines Market size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Product Type

Table 23: MEA Pneumococcal Vaccines Market Size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Distribution Channel 

Table 24: Global Pneumococcal Vaccines Market Size (US$ Mn) Forecast By Region, 2021–2031

Table 25: Global Pneumococcal Vaccines Market size Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Product Type

Table 26: Global Pneumococcal Vaccines Market size (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031 , By Distribution Channel

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 01: Market Size (US$ Mn) by Region (2021A & 2031F)

Figure 02: Global Pneumococcal Vaccines Market Value Share By Product Type 2021 (A)

Figure 03: Global Pneumococcal Vaccines Market Value Share By Product Type 2021 (A)

Figure 04: Tiered-price Policies Among Vaccine Manufacturers

Figure 05: Pneumococcal Vaccine Procured Volumes 2021-2031 (in millions of doses) 

Figure 06: Countries Approved for Gavi's Pneumococcal Vaccine Support-

Figure 07: Trends in Invasive Pneumococcal Diseases Among Children Aged <5 year Old, 2021–2031

Figure 08: Summary of AMC Financial Process Flow And Funds Disbursed in Private-public Partnerships (Inception to 31 December 2021) 

Figure 09: Countries With Pneumococcal Conjugate Vaccine in The National Immunization Program and Planned Introductions (In 2018)

Figure 10: Global Coverage of Older Vaccines vs. Newer Vaccines (2016)

Figure 11: Comparison of PCV Uptake in High-income, Gavi-eligible and Gavi-ineligible Countries, 2016–2020 

Figure 12: Number of Children Who Were Unvaccinated, By Country

Figure 13: Distribution of Industry Sponsored Clinical Programs for Pneumococcal Vaccines, by Phase

Figure 14: Distribution of Industry Sponsored Clinical Programs for Pneumococcal Vaccines, by Age Group

Figure 15: Geographical Distribution of Clinical Trials for Pneumococcal Vaccines (2021)

Figure 16: Distribution of Industry Sponsored Clinical Programs for RSV Vaccines, by Phase

Figure 17: Distribution of Industry Sponsored Clinical Programs for RSV Vaccines, by Age Group

Figure 18: Geographical Distribution of Clinical Trials for RSV Vaccines (2021)

Figure 19: North America Pneumococcal Vaccines Market Split By Product Type (2018)

Figure 20: North America Pneumococcal Vaccines Market Split By Distribution Channel (2018)

Figure 21: North America Pneumococcal Vaccines Market Split By Country (2018)

Figure 22: North America Pneumococcal Vaccines Market Size Analysis, 2021–2031

Figure 23: North America Pneumococcal Vaccines Market Forecast & Y-o-Y growth, 2021–2031 

Figure 24: U.S. Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031

Figure 25: U.S. Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 

Figure 26: Canada Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031

Figure 27: Canada Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 

Figure 28: North America Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031, By Pneumococcal Polysaccharide Vaccines

Figure 29: North America Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 By Pneumococcal Polysaccharide Vaccines

Figure 30: North America Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031, By Pneumococcal Conjugate Vaccines

Figure 31: North America Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 By Pneumococcal Conjugate Vaccines

Figure 32: North America Pneumococcal Vaccines Market Attractiveness Analysis By Product Type, 2021–2031 

Figure 33: North America Pneumococcal Vaccines Market Attractiveness Analysis By Distribution Channel, 2021–2031 

Figure 34: North America Pneumococcal Vaccines Market Attractiveness Analysis By Country, 2021–2031 

Figure 35: Latin America Pneumococcal Vaccines Market Split By Product Type (2018)

Figure 36: Latin America Pneumococcal Vaccines Market Split By Distribution Channel (2018)

Figure 37: Latin America Pneumococcal Vaccines Market Split By Country (2018)

Figure 38: Latin America Pneumococcal Vaccines Market Size Analysis, 2021–2031

Figure 39: Latin America Pneumococcal Vaccines Market Forecast & Y-o-Y growth, 2021–2031 

Figure 40: Brazil Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031

Figure 41: Brazil Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 

Figure 42: Mexico Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031

Figure 43: Mexico Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 

Figure 44: Rest of Latin America Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031

Figure 45: Rest of Latin America Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 

Figure 46: Latin America Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031, By Pneumococcal Polysaccharide Vaccines

Figure 47: Latin America Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 By Pneumococcal Polysaccharide Vaccines

Figure 48: Latin America Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031, By Pneumococcal Conjugate Vaccines

Figure 49: Latin America Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 By Pneumococcal Conjugate Vaccines

Figure 50: Latin America Pneumococcal Vaccines Market Attractiveness Analysis By Product Type, 2021–2031 

Figure 51: Latin America Pneumococcal Vaccines Market Attractiveness Analysis By Distribution Channel, 2021–2031 

Figure 52: Latin America Pneumococcal Vaccines Market Attractiveness Analysis By Country, 2021–2031 

Figure 53: Western Europe Pneumococcal Vaccines Market Split By Product Type (2018)

Figure 54: Western Europe Pneumococcal Vaccines Market Split By Distribution Channel (2018)

Figure 55: Western Europe Pneumococcal Vaccines Market Split By Country (2018)

Figure 56: Western Europe Pneumococcal Vaccines Market Size Analysis, 2021–2031

Figure 57: Western Europe Pneumococcal Vaccines Market Forecast & Y-o-Y growth, 2021–2031 

Figure 58: U.K. Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031

Figure 59: U.K. Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 

Figure 60: France Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031

Figure 61: France Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 

Figure 62: Germany Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031

Figure 63: Germany Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 

Figure 64: Italy Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031

Figure 65: Italy Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 

Figure 66: Spain Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031

Figure 67: Spain Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 

Figure 68: Rest of Western Europe Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031

Figure 69: Rest of Western Europe Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 

Figure 70: Western Europe Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031, By Pneumococcal Polysaccharide Vaccines

Figure 71: Western Europe Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 By Pneumococcal Polysaccharide Vaccines

Figure 72: Western Europe Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031, By Pneumococcal Conjugate Vaccines

Figure 73: Western Europe Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 By Pneumococcal Conjugate Vaccines

Figure 74: Western Europe Pneumococcal Vaccines Market Attractiveness Analysis By Product Type, 2021–2031 

Figure 75: Western Europe Pneumococcal Vaccines Market Attractiveness Analysis By Distribution Channel, 2021–2031 

Figure 76: Western Europe Pneumococcal Vaccines Market Attractiveness Analysis By Country, 2021–2031 

Figure 77: Eastern Europe Pneumococcal Vaccines Market Split By Product Type (2018)

Figure 78: Eastern Europe Pneumococcal Vaccines Market Split By Distribution Channel (2018)

Figure 79: Eastern Europe Pneumococcal Vaccines Market Split By Country (2018)

Figure 80: Eastern Europe Pneumococcal Vaccines Market Size Analysis, 2021–2031

Figure 81: Eastern Europe Pneumococcal Vaccines Market Forecast & Y-o-Y growth, 2021–2031 

Figure 82: Russia Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031

Figure 83: Russia Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 

Figure 84: Poland Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031

Figure 85: Poland Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 

Figure 86: Rest of Eastern Europe Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031

Figure 87: Rest of Eastern Europe Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 

Figure 88: Eastern Europe Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031, By Pneumococcal Polysaccharide Vaccines

Figure 89: Eastern Europe Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 By Pneumococcal Polysaccharide Vaccines

Figure 90: Eastern Europe Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031, By Pneumococcal Conjugate Vaccines

Figure 91: Eastern Europe Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 By Pneumococcal Conjugate Vaccines

Figure 92: Eastern Europe Pneumococcal Vaccines Market Attractiveness Analysis By Product Type, 2021–2031 

Figure 93: Eastern Europe Pneumococcal Vaccines Market Attractiveness Analysis By Distribution Channel, 2021–2031 

Figure 94: Eastern Europe Pneumococcal Vaccines Market Attractiveness Analysis By Country, 2021–2031 

Figure 95: APEJ Pneumococcal Vaccines Market Split By Product Type (2018)

Figure 96: APEJ Pneumococcal Vaccines Market Split By Distribution Channel (2018)

Figure 97: APEJ Pneumococcal Vaccines Market Split By Country (2018)

Figure 98: APEJ Pneumococcal Vaccines Market Size Analysis, 2021–2031

Figure 99: APEJ Pneumococcal Vaccines Market Forecast & Y-o-Y growth, 2021–2031 

Figure 100: India Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031

Figure 101: India Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 

Figure 102: Australia & New Zealand Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031

Figure 103: Australia & New Zealand Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 

Figure 104: China Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031

Figure 105: China Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 

Figure 106: ASEAN Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031

Figure 107: ASEAN Australia & New Zealand Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 

Figure 108: Rest of APEJ Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031

Figure 109: Rest of APEJ Australia & New Zealand Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 

Figure 110: APEJ Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031, By Pneumococcal Polysaccharide Vaccines

Figure 111: APEJ Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 By Pneumococcal Polysaccharide Vaccines

Figure 112: APEJ Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031, By Pneumococcal Conjugate Vaccines

Figure 113: APEJ Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 By Pneumococcal Conjugate Vaccines

Figure 114: APEJ Pneumococcal Vaccines Market Attractiveness Analysis By Product Type, 2021–2031 

Figure 115: APEJ Pneumococcal Vaccines Market Attractiveness Analysis By Distribution Channel, 2021–2031 

Figure 116: APEJ Pneumococcal Vaccines Market Attractiveness Analysis By Country, 2021–2031 

Figure 117: Japan Pneumococcal Vaccines Market Split By Product Type (2018)

Figure 118: Japan Pneumococcal Vaccines Market Split By Distribution Channel (2018)

Figure 119: Japan Pneumococcal Vaccines Market Size Analysis, 2021–2031

Figure 120: Japan Pneumococcal Vaccines Market Forecast & Y-o-Y growth, 2021–2031 

Figure 121: Japan Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031, By Pneumococcal Polysaccharide Vaccines

Figure 122: Japan Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 By Pneumococcal Polysaccharide Vaccines

Figure 123: Japan Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031, By Pneumococcal Conjugate Vaccines

Figure 124: Japan Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 By Pneumococcal Conjugate Vaccines

Figure 125: Japan Pneumococcal Vaccines Market Attractiveness Analysis By Product Type, 2021–2031 

Figure 126: Japan Pneumococcal Vaccines Market Attractiveness Analysis By Distribution Channel, 2021–2031 

Figure 127: MEA Pneumococcal Vaccines Market Split By Product Type (2018)

Figure 128: MEA Pneumococcal Vaccines Market Split By Distribution Channel (2018)

Figure 129: MEA Pneumococcal Vaccines Market Split By Country (2018)

Figure 130: MEA Pneumococcal Vaccines Market Size Analysis, 2021–2031

Figure 131: MEA Pneumococcal Vaccines Market Forecast & Y-o-Y growth, 2021–2031 

Figure 132: South Africa Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031

Figure 133: South Africa Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 

Figure 134: GCC Countries Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031

Figure 135: GCC Countries Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 

Figure 136: Rest of MEA Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031

Figure 137: Rest of MEA Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 

Figure 138: MEA Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031, By Pneumococcal Polysaccharide Vaccines

Figure 139: MEA Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 By Pneumococcal Polysaccharide Vaccines

Figure 140: MEA Pneumococcal Vaccines Market Size (US$ Mn) Analysis, 2021–2031, By Pneumococcal Conjugate Vaccines

Figure 141: MEA Pneumococcal Vaccines Market Forecast & Y-o-Y Growth (%), 2021–2031 By Pneumococcal Conjugate Vaccines

Figure 142: MEA Pneumococcal Vaccines Market Attractiveness Analysis By Product Type, 2021–2031 

Figure 143: MEA Pneumococcal Vaccines Market Attractiveness Analysis By Distribution Channel, 2021–2031 

Figure 144: MEA Pneumococcal Vaccines Market Attractiveness Analysis By Country, 2021–2031 

Figure 145 : Global Pneumococcal Vaccines Market Share Analysis (%) By Region, 2021 & 2031

Figure 146: Global Pneumococcal Vaccines Market Y-o-Y Growth (%) By Region, 2021–2031

Figure 147: Global Pneumococcal Vaccines Market Attractiveness Analysis By Region, 2021–2031 

Figure 148: Global Pneumococcal Vaccines Market Share Analysis (%) By Product Type, 2021 & 2031

Figure 149: Global Pneumococcal Vaccines Market Y-o-Y Growth (%) By Product Type, 2021–2031

Figure 150: Global Pneumococcal Vaccines Market Attractiveness Analysis By Product Type, 2021–2031 

Figure 151: Global Pneumococcal Vaccines Share Analysis (%) By Distribution Channel, 2021 & 2031

Figure 152: Global Pneumococcal Vaccines Market Y-o-Y Growth (%) By Distribution Channel, 2021–2031

Figure 153: Global Pneumococcal Vaccines Market Attractiveness Analysis By distribution channel , 2021–2031 

Figure 154: Global Pneumococcal Vaccines Market Value Analysis and Forecast, 2021–2028 (US$ Mn)

Figure 155: Global Pneumococcal Vaccines Market Absolute $ Opportunity (US$ Mn), 2021–2031

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports
Google translate

Pneumococcal Vaccines Market